Positive adnexal or uterine serosal involvement in stage IIIC XXXX is an adverse factor for recurrence.

@entity1204 @entity1 @entity3
OBJECTIVES: Clinical and pathological significance of stage IIIC @entity1204 is unclear. Our study was designed to determine the risk of recurrence among @entity1 with stage IIIC @entity1204 according to different pathological findings. METHODS: We retrospectively reviewed all @entity1 with @entity1204 (n = 48) treated in our institution between 1996 and 2005. @entity1 without comprehensive surgical staging were excluded. @entity1 were classified into two groups: with adnexae and/or uterine serosal @entity3 (group A, n = 18) and without @entity3 (group B, n = 20). Cox proportional hazards model was used for multiple regression analysis. RESULTS: Mean age was 64 years (range 46-90). Eighteen @entity1 received adjuvant chemotherapy and pelvic radiotherapy, 17 received pelvic radiotherapy alone, and 11 received chemotherapy or hormonotherapy. At a median follow-up of 26.7 months, 12 had recurrence of the disease. Serosal and/or adnexal involvement was a negative independent prognostic factor for disease-free survival [relative risk = 3.75 (1.01-13.9); p = 0.04], whereas histological type, grade, depth of invasion and age at diagnosis had no influence. CONCLUSION: @entity1 with stage IIIC @entity1204 and @entity3 to adnexae and/or serosa have a higher risk of recurrence than those with node @entity3 alone. Optimal adjuvant therapy for these groups remains unclear.
